Table 1.
Turnaround time (in days) for infants born and tested at cohort study facilities at birth and six weeks and infants born at noncohort study facilities tested at six weeks between January–June 2016.
| Blood draw to receipt at NRL+ | Receipt of specimen at NRL to testing at NRL | Testing at NRL to result receipt at health facility | Result receipt at facility to receipt by caregiver | Blood draw to receipt by caregiver | Infant age at receipt by caregiver | Result receipt by caregiver to treatment initiation | Blood draw to ART initiation | Infant age at treatment initiation | |
|---|---|---|---|---|---|---|---|---|---|
| Birth (cohort study facilities only) | |||||||||
| All infants, N∗, | 40 | 48 | 43 | 60 | 54 | 61 | |||
| Median time (IQR) | 22.5 | 7.0 | 15.0 | 14.5 | 76.5 | 78.0 | |||
| (19.0–30.0) | (3.5–10.5) | (10.0–27.0) | (4.0–33.5) | (48.0–98.0) | (48.0–102.0) | ||||
| All infants, range | 3.0–64.0 | 2.0–64.0 | 0–210.0 | 0–97.0 | 36.0–164 | 32.0–174.0 | |||
| HIV-infected infant (n = 1) | 25.0 | 5.0 | 7.0 | 1.0 | 38.0 | 43.0 | 0 | 38.0 | 43.0 |
|
| |||||||||
| 6-week DNA-PCR (cohort study facilities) | |||||||||
| All infants, N | 44 | 53 | 48 | 58 | 46 | 58 | |||
| Median time (IQR) | 21.0 | 6.0 | 15.5 | 13.0 | 63.0 | 105.5 | |||
| (14.0–31.5) | (3.0–8.0) | (7.5–26.5) | (3.0–28.0) | (52.0–72.0) | (94.0–118.0) | ||||
| All infants, range | 1.0–77.0 | 0–26.0 | 0–65.0 | 0–99.0 | 35.0–158.0 | 62.0–201.0 | |||
| HIV-infected infant (n = 1) | 28.0 | 8.0 | 8.0 | 5.0 | 49.0 | 102.0 | 0 | 49.0 | 102.0 |
|
| |||||||||
| 6-week DNA-PCR (noncohort study facilities) | |||||||||
| All infants, N | 49 | 37 | 18 | 27 | 30 | 30 | |||
| Median time (IQR) | 17.0 | 6.0 | 15.0 | 17.0 | 70.0 | 111.5 | |||
| (11.0–27.0) | (4.0–9.0) | (8.0–21.0) | (8.0–31.0) | (56.0–74.0) | (104.0–121.0) | ||||
| All infants, range | 0–57.0 | 0–78.0 | 7.0–66.0 | 0–96.0 | 24.0–154.0 | 72.0–199.0 | |||
| HIV-infected infants, N | 3 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 |
| Median time (IQR) | 18.0 | 10.0 | 15.0 | 7.0 | 49.0 | 94.5 | 10.0 | 66.0 | 112.0 |
| (11.0–24.0) | (5.0–15.0) | (1.0–13.0) | (42.0–56.0) | (87.0–102.0) | |||||
| HIV-infected infants, range | 11.0–24.0 | 5.0–15.0 | — | 1.0–13.0 | 42.0–56.0 | 87.0–102.0 | — | — | — |
∗The number of infants contributing to each step varied as some dates were not available to calculate all steps for each infant. +All values are presented in days except for the number of infants contributing to each step (N); ART: antiretroviral therapy; IQR: interquartile range; N: number; NRL: National Reference Laboratory.